Colorectal Cancer News and Research RSS Feed - Colorectal Cancer News and Research

Colorectal Cancer is cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus). In the United States, it is the fourth most common cancer in men and women. Caught early, it is often curable.
CCO wants men and women in Ontario to get screened for colorectal cancer

CCO wants men and women in Ontario to get screened for colorectal cancer

March is Colorectal Cancer Awareness Month, and Cancer Care Ontario wants men and women to start thinking about getting screened. [More]
SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France. [More]
Key questions about colorectal cancer answered

Key questions about colorectal cancer answered

Colorectal cancer is the fourth most common cancer in the U.S., with more than 136,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years. [More]
Study findings raise questions about additional value of cancer care in the U.S.

Study findings raise questions about additional value of cancer care in the U.S.

Despite sharp increases in spending on cancer treatment, cancer mortality rates in the United States have decreased only modestly since 1970, Samir Soneji, PhD of Dartmouth's Norris Cotton Cancer Center and The Dartmouth Institute for Health Policy & Clinical Practice has found. [More]
EMA extends approval of Vectibix plus FOLFIRI as first-line treatment for wild-type RAS mCRC

EMA extends approval of Vectibix plus FOLFIRI as first-line treatment for wild-type RAS mCRC

Amgen today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion to extend the marketing authorization for Vectibix (panitumumab) to include combination with FOLFIRI (an irinotecan-based chemotherapy) as first-line treatment in adult patients with wild-type RAS metastatic colorectal cancer (mCRC). [More]
Cancer Care Ontario raises awareness about colorectal cancer

Cancer Care Ontario raises awareness about colorectal cancer

March is Colorectal Cancer Awareness Month and Cancer Care Ontario (CCO) is on a mission to raise awareness about an organ that doesn't get the attention it deserves. [More]
Taiho announces submission of TAS-102 MAA to EMA for treatment of mCRC

Taiho announces submission of TAS-102 MAA to EMA for treatment of mCRC

Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC). [More]
Insurance status linked to patient safety, quality of care for patients with brain tumors

Insurance status linked to patient safety, quality of care for patients with brain tumors

Patients that are on Medicaid or uninsured have higher rates of reportable patient safety and quality of care issues during hospitalization for brain tumors, reports a study in the March issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]
NYU Langone reminds people about importance of screening and preventing colorectal cancer

NYU Langone reminds people about importance of screening and preventing colorectal cancer

According to the U.S. Centers for Disease Control and Prevention, colorectal cancer is the second leading cause of cancer death in the United States. However, according to Mark Pochapin, MD, the Sholtz/Leeds professor of Gastroenterology and director of the Division of Gastroenterology at NYU Langone Medical Center : "With early screening and prevention, this is one cancer that is highly curable and often preventable." [More]
Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). [More]
Scientists find new links between inflammation and tissue regeneration

Scientists find new links between inflammation and tissue regeneration

Almost all injuries, even minor skin scratches, trigger an inflammatory response, which provides protection against invading microbes but also turns on regenerative signals needed for healing and injury repair - a process that is generally understood but remains mysterious in its particulars. [More]
PCORI funds five patient-centered comparative effectiveness research studies

PCORI funds five patient-centered comparative effectiveness research studies

The Patient-Centered Outcomes Research Institute Board of Governors today approved awards totaling more than $64 million to fund five large patient-centered comparative effectiveness research (CER) studies that will answer critical clinical questions about care for cancer, back pain, and stroke. [More]
Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced the New Drug Application (NDA) for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), has been accepted for review by the U.S. Food and Drug Administration. [More]
Facts about precision medicine

Facts about precision medicine

President Barack Obama is requesting an increase of $215 million in the 2016 federal budget to launch the Precision Medicine Initiative. This boost in funding for research will give genetic causes of cancer a national focus specifically around precision or "personalized" treatments for cancer in the future. [More]
Oncolytics announces completion of patient enrollment in REOLYSIN Phase II colorectal cancer study

Oncolytics announces completion of patient enrollment in REOLYSIN Phase II colorectal cancer study

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer (IND 210). The trial is being sponsored and conducted by the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario. [More]
OHSU Knight Cancer Institute funds 17 community projects to decrease impact of cancer on Oregonians

OHSU Knight Cancer Institute funds 17 community projects to decrease impact of cancer on Oregonians

The Knight Cancer Institute at Oregon Health & Science University awarded $462,656 to 17 projects statewide as part of the first round of funding offered through its Community Partnership Program. The program's goal is to address community-identified needs to ultimately decrease the impact of cancer on Oregonians. [More]
Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease among men and women in Germany. So-called microsatellite stable colorectal cancer with mutations in the BRAF gene represents a particularly aggressive form. [More]
Ten hospital programs recognized for improving health of local communities

Ten hospital programs recognized for improving health of local communities

From street outreach in Burlington, Vermont to a New York City taxi network to infant mortality prevention in Detroit, ten hospital programs were named Programs of Excellence for their achievements in improving the health of local communities. Each program was awarded $10,000 through the Hospital Charitable Services Awards, a national program sponsored by Jackson Healthcare. [More]
Cancer researchers find important clues to why tumor cells become 'good' or 'bad'

Cancer researchers find important clues to why tumor cells become 'good' or 'bad'

For the first time, Keck Medicine of the University of Southern California cancer researchers have traced the origins of colorectal cancer cells, finding important clues to why tumor cells become "good" or "bad," with the potential of stopping them before they start. [More]
Salicylates drugs reduce proliferation, viability of cultured vestibular schwannoma cells

Salicylates drugs reduce proliferation, viability of cultured vestibular schwannoma cells

Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that salicylates, a class of non-steroidal inflammatory drugs (NSAIDs), reduced the proliferation and viability of cultured vestibular schwannoma cells that cause a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus. [More]